Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,953 total articles
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing novel FASN inhibitors for metabolic and fibrotic diseases, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference with a fireside chat scheduled on May 19, 2026. The event will be webcast and archived for investors and me…
OIO Group announced it has entered into a term sheet for the proposed acquisition of a privately held German automotive engineering and low-volume production platform. The acquisition aims to strengthen OIO's engineering depth, prototype capability, and operational infrastructure in Europe, supporting the ongoing development and production of the D…
Can-Fite BioPharma Ltd. announced advancement of its pancreatic cancer drug Namodenoson into a Phase 2b study combining it with immunotherapy. This follows encouraging Phase 2a data showing favorable safety and clinical activity in advanced pancreatic adenocarcinoma patients. The company plans to discuss study design and partnership negotiations at…
Corbus Pharmaceuticals Holdings, a clinical-stage biotech company focusing on oncology and obesity therapies, disclosed that CEO Yuval Cohen will present at both the RBC Capital Markets and Jefferies Global Healthcare Conferences in May and June 2026, respectively. These presentations aim to update investors on company progress, including their pip…
Victoria’s Secret & Co. invites investors and analysts to listen to its Q1 2026 earnings webcast on June 2 at 8:30 a.m. ET, with the related financial release anticipated approximately one hour prior. The company operates globally with leading brands including Victoria’s Secret, PINK, and Adore Me, and provides a detailed safe harbor statement high…
Nurix Therapeutics, a clinical-stage biopharmaceutical company specializing in targeted protein degradation therapies, announced that CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference and the Jefferies Global Healthcare Conference in May and June 2026. These events are opportunities for Nurix to present …
Humacyte, Inc. (Nasdaq: HUMA) announced its first quarter 2026 financial results, highlighting increased sales of its vascular graft product Symvess, key strategic hires in commercial and surgical leadership, acceptance of its marketing application in Israel, a new purchase commitment in Saudi Arabia, and upcoming top-line interim Phase 3 trial res…
Opus Genetics, a clinical-stage biopharmaceutical company specializing in gene therapies for inherited retinal diseases, announced its management will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026. The company focuses on developing one-time gene therapy treatments addressing genetic causes of severe retinal di…
BioCryst Pharmaceuticals announced new real-world data presentations at ISPOR 2026 highlighting the significant healthcare resource utilization and quality-of-life impact of hereditary angioedema (HAE) on pediatric patients and their caregivers. The studies underscore ongoing unmet needs and the importance of optimized disease management in this ra…
Kornit Digital Ltd. announced its Q1 2026 results with revenues of $48.5 million at the top end of guidance, a 103% increase in All-Inclusive Click (AIC) revenues year-over-year, and positive operating cash flow for the tenth consecutive quarter. The company highlighted strong traction in digital fashion and textile production driven by product inn…
Beam Therapeutics announced its CEO, John Evans, will present at the 2026 RBC Capital Markets Global Healthcare Conference. The presentation will highlight Beam's advancements in precision genetic medicines using their proprietary base editing technology. The conference presentation will be webcast live and archived for investor access.
PDS Biotechnology Corporation announced its first quarter 2026 financial results and clinical updates, highlighting progress in its immunotherapy clinical trials including amendments to the VERSATILE-003 Phase 3 trial for HPV16-positive head and neck cancer and positive biomarker data from metastatic colorectal cancer and prostate cancer trials. Th…
RTB Digital, Inc. announced the closing of its merger with RYVYL Inc. and the commencement of trading on the Nasdaq Capital Market under the ticker RTB. The company offers a pioneering AI, DeFi, and Web3 enabled enterprise media platform designed to transform the global premium media industry by integrating decentralized publishing, data protection…
Tower Semiconductor announced its first quarter 2026 financial results showing a 15% year-over-year increase in revenue to $414 million, along with significant growth in gross profit and operating profit. The company projects record revenue of $455 million for Q2 2026, driven by robust demand and strategic advances, particularly in silicon photonic…
Kamada Ltd. reported Q1 2026 revenues of $45.2 million, a 3% year-over-year increase, with adjusted EBITDA of $11.6 million and net income rising 4% to $4.1 million. Despite a temporary shipment delay, demand for key products like KEDRAB in the U.S. and KAMRAB and VARIZIG in international markets is rising. The company reaffirms its 2026 revenue gu…
Atea Pharmaceuticals announced that three abstracts highlighting their progress in oral antiviral treatments for viral hepatitis have been accepted for presentation at the EASL Congress 2026. The presentations feature clinical and preclinical data on their hepatitis C fixed-dose combination regimen (bemnifosbuvir and ruzasvir) showing promise in Ph…
Skeena Gold & Silver released its 2025 Sustainability Report titled 'Where Voices Meet, Progress Follows,' detailing significant milestones including an Impact Benefit Agreement with the Tahltan Central Government, environmental permits secured for the Eskay Creek Gold-Silver project, and strong workforce diversity and safety records. The company i…
TransUnion declared a cash dividend of $0.125 per share for the first quarter of 2026, payable on June 11, 2026, to shareholders of record as of May 27, 2026. This reflects the company's ongoing commitment to returning value to its shareholders amid its continued business operations in global information and insights services.
Zenas BioPharma has dosed the first subject in a Phase 1 clinical trial for ZB021, a novel oral IL-17AA/AF inhibitor aimed at treating autoimmune diseases such as plaque psoriasis. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers, with initial data expected by the end of 2026 and proof-of-concept results in pso…
Eos Energy Enterprises reported a strong first quarter of 2026 with a 445% year-over-year revenue increase to $57 million, achieving record production outputs and improving margins. The company launched Frontier Power USA in partnership with Cerberus, a new independent entity to develop and operate large-scale long-duration energy storage projects,…
Eos Energy Enterprises and Cerberus Capital Management announced the creation of Frontier Power USA, a joint venture focused on building and operating long-duration energy storage projects using Eos's proprietary zinc bromide Z3 technology. Fronted by $100 million equity from Cerberus and a 2 GWh manufacturing capacity reservation, Frontier Power U…
Veru Inc., a U.S.-based late clinical stage biopharmaceutical company, announced its fiscal 2026 Q2 financial results showing reduced losses and increased cash reserves. Simultaneously, the company provided a corporate update highlighting active enrollment in the Phase 2b PLATEAU clinical trial, evaluating enobosarm plus semaglutide for obesity man…
Aprea Therapeutics announced its first quarter 2026 financial results and corporate update, including progress in its Phase 1 trial ACESOT-1051 for APR-1051, a WEE1 inhibitor, with two partial responses observed and favorable tolerability. The company closed an oversubscribed $30 million private placement to bolster its cash position, now at $46.5 …
Global-e Online Ltd. reported robust Q1 2026 financial results with Gross Merchandise Value (GMV) growing 40% year-over-year to $1.742 billion, revenues up 33% to $252.1 million, and Adjusted EBITDA more than 50% higher to $50.2 million, reflecting strong operational leverage. The company expanded its merchant base across multiple international reg…
Voyager Therapeutics announced positive three-month GLP toxicology data for VY1706, their investigational tau silencing gene therapy for Alzheimer’s disease, showing good tolerability and significant tau protein reduction in non-human primates. The company expects to submit an IND application in Q2 2026 and initiate clinical trials in the second ha…
